Literature DB >> 7615813

Superantigen properties of a human sialoprotein involved in gut-associated immunity.

G J Silverman1, P Roben, J P Bouvet, M Sasano.   

Abstract

Protein Fv (pFv) is a recently described 175-kD gut-associated sialoprotein with a potent capacity for augmentation of antibody-dependent immune functions. To investigate the molecular basis for Fab-mediated binding of pFv, we evaluated a panel of 52 monoclonal IgM and found that approximately 40% bound pFv. Whereas the majority (> or = 75%) of V H3 and V H6 IgM strongly bound pFv, only a small minority (< 20%) of IgM from other V H families bound pFv, and these antibodies had weaker binding interactions. Inhibition studies suggested that all binding occurred at the same (or overlapping) site(s) on pFv. Surface plasmon resonance studies demonstrated binding affinity constants up to 6.7 x 10(8) M-1 for pFv. Biopanning of IgM and IgG Fab phage-display libraries with pFv preferentially selected for V H3 and V H6 antibodies, but also obtained certain V H4 IgM. V H sequence analyses of 36 pFv-binding antibodies revealed that binding did not correlate with CDR sequence, JH, or L chain usage. However, there was preferential selection of pFv binders with V H CDR3 of small size. These studies demonstrate that a protein which enhances immune defense in the gut has structural and functional properties similar to known superantigens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7615813      PMCID: PMC185215          DOI: 10.1172/JCI118051

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  63 in total

1.  Interactions in the fourth dimension.

Authors:  R Granzow; R Reed
Journal:  Biotechnology (N Y)       Date:  1992-04

2.  A majority of Ig H chain cDNA of normal human adult blood lymphocytes resembles cDNA for fetal Ig and natural autoantibodies.

Authors:  C Huang; B D Stollar
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

3.  Structure and multiplicity of genes for the human immunoglobulin heavy chain variable region.

Authors:  G Matthyssens; T H Rabbitts
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

4.  Immunoglobulin heavy chain gene expression in peripheral blood B lymphocytes.

Authors:  C Huang; A K Stewart; R S Schwartz; B D Stollar
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

5.  Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells.

Authors:  V Patella; J P Bouvet; G Marone
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

6.  Immunoglobulin VH3 gene products: natural ligands for HIV gp120.

Authors:  L Berberian; L Goodglick; T J Kipps; J Braun
Journal:  Science       Date:  1993-09-17       Impact factor: 47.728

7.  Nonimmune macromolecular complexes of Ig in human gut lumen. Probable enhancement of antibody functions.

Authors:  J P Bouvet; R Pirès; S Iscaki; J Pillot
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

8.  Molecular selection of human antibodies with an unconventional bacterial B cell antigen.

Authors:  M Sasano; D R Burton; G J Silverman
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

9.  High frequency of somatically mutated IgM molecules in the human adult blood B cell repertoire.

Authors:  J H van Es; F H Meyling; T Logtenberg
Journal:  Eur J Immunol       Date:  1992-10       Impact factor: 5.532

10.  The three-dimensional structure of the fab' fragment of a human myeloma immunoglobulin at 2.0-angstrom resolution.

Authors:  R J Poljak; L M Amzel; B L Chen; R P Phizackerley; F Saul
Journal:  Proc Natl Acad Sci U S A       Date:  1974-09       Impact factor: 11.205

View more
  10 in total

1.  Superantigens and autoantigens may be involved in the pathogenesis of gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  T Hashimoto; M Takishita; M Kosaka; T Sano; T Matsumoto
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

Review 2.  Diversity of antibody-mediated immunity at the mucosal barrier.

Authors:  J P Bouvet; V A Fischetti
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

3.  The role of somatic mutation in determining the affinity of anti-DNA antibodies.

Authors:  M Behrendt; L J Partridge; B Griffiths; M Goodfield; M Snaith; N J Lindsey
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

4.  Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans.

Authors:  C P Quan; A Berneman; R Pires; S Avrameas; J P Bouvet
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

5.  Novel unconventional binding site in the variable region of immunoglobulins.

Authors:  K Rajagopalan; G Pavlinkova; S Levy; P R Pokkuluri; M Schiffer; B E Haley; H Kohler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

6.  Pathogenesis of B-cell superantigen-induced immune complex-mediated inflammation.

Authors:  Amy L Anderson; Romeo Sporici; John Lambris; David Larosa; Arnold I Levinson
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

7.  Repertoire cloning of lupus anti-DNA autoantibodies.

Authors:  P Roben; S M Barbas; L Sandoval; J M Lecerf; B D Stollar; A Solomon; G J Silverman
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

8.  A B cell superantigen-induced persistent "Hole" in the B-1 repertoire.

Authors:  G J Silverman; S P Cary; D C Dwyer; L Luo; R Wagenknecht; V E Curtiss
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

9.  A B-Cell Superantigen Induces the Apoptosis of Murine and Human Malignant B Cells.

Authors:  Daniela Lorenzo; Alejandra Duarte; Juliana Mundiñano; Paula Berguer; Irene Nepomnaschy; Isabel Piazzon
Journal:  PLoS One       Date:  2016-09-07       Impact factor: 3.240

10.  IgG Conformer's Binding to Amyloidogenic Aggregates.

Authors:  Monichan Phay; Alfred T Welzel; Angela D Williams; Helen P McWilliams-Koeppen; Veronika Blinder; Tiernan T O'Malley; Alan Solomon; Dominic M Walsh; Brian O'Nuallain
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.